Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(2):137-142
DOI: 10.5428/pcar20190215
Analysis of the use of Chinese patent medicines containing toxic herbs in the Shanghai Pudong New Area People’s Hospital from 2013 to 2016
1. DUAN Luqing1(1.Department of Pharmacy,Shanghai Pudong New Area People’s Hospital,Shanghai 201299,China duanluqing@sina.com)
2. YU Yun2( 2. School of Pharmacy,Bengbu Medical College,Anhui Bengbu 233030,China )
3. ZHANG Qingqing2( 2. School of Pharmacy,Bengbu Medical College,Anhui Bengbu 233030,China )
4. HUANG Jin1(1.Department of Pharmacy,Shanghai Pudong New Area People’s Hospital,Shanghai 201299,China john70550@163.com)
5. 3(3. Department of Pharmacy,Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 200437,China john70550@163.com)
ABSTRACT  Objective: To investigate the use of Chinese patent medicines containing toxic herbs in Shanghai Pudong New Area People’s Hospital (hereafter referred to as our hospital),so as to provide reference for their rational use clinically. Methods: Varieties of traditional Chinese patent medicines containing toxic herbs used in our hospital from 2013 to 2016 were surveyed and analyzed,and their toxic ingredients,drug categories,consumption sums,drug use intensity (DDDs),prescription rationality and adverse drug reactions (ADRs) were systematically analyzed. Results: There were 30 categories of Chinese patent medicines containing toxic herbs,and the top 3 consumption sums of the drugs were those used in internal medicine,oncology and surgery. As compared with the consumption sums in 2013,the consumption sums of these 3 categories of medicines in 2016 increased by 85.63%,70.82% and 37.93%,with Biqi capsules always ranging the top 3 of consumption sums and DDDs increased most significantly in 2016. The medication intensity of Shenshuaining and Xiaoer Chiqiaoqingre granules also increased significantly,as compared with that of previous 2 years. Through prescription evaluations and medical advice reviews and analyses,the main problems associated with Chinese patent medicines containing toxic herbs were as follows: improper drug dosage (accounting for 46.73%),improper medications (accounting for 29.17%) and repeated medications (accounting for 12.96%). Thirteen reports concerning ADRs of Chinese patent medicines containing toxic herbs accounted for 13.98% of all the ADRs reports of Chinese patent medicines. Conclusion: It is important to intensify theoretical supervision of traditional Chinese medicines,strictly control the drugs for proper indications and dosage,and in the meantime strengthen prescription evaluation and drug monitoring,so as to ensure medication safety for the benefits of patients.
Welcome to PCAR! You are the number 48 reader of this article!
Please cite this article as:
DUAN Luqing1,YU Yun2,ZHANG Qingqing2,HUANG Jin1,3,. Analysis of the use of Chinese patent medicines containing toxic herbs in the Shanghai Pudong New Area People’s Hospital from 2013 to 2016[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(2): 137-142.
References:
1. JING Yongkui,WANG Long,XIA Lijuan,et al.Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo[J]. Blood,2001,97(1):264-269.
2. ZHANG Bihua,HU Xin,JIN Pengfei,et al. Utilization analysis and adverse drug reaction of Chinese patent medicines containing poisonous ingredients in our hospital[J]. Chin Pharm J,2013,48(13):1126-1129. In Chinese with English abstract.
3. ZHANG Zheng,ZHANG Jiali. Analysis of 45 cases of adverse drug reactions induced by Xiaojinwan and Xiaojinjiaonang[J]. Chin J Pharmacovig,2012,9(4):242-244. In Chinese with English abstract.
4. ZHANG Tai,LIAN Jia.Problems and suggestions of using Chinese patent medicine for clearing heat in clinical practice of pediatrics[J]. J Tradit Chin Med,2017,58(2):119-122. In Chinese.
5. LIU Yang,XIAO Longhao,LIU Ziran,et al. Analysis of adverse drug reactions of traditional Chinese medicine injections through ADRs information bulletin[J]. J Tianjin Univ Tradit Chin Med,2018,37(2):92-95. In Chinese.
6. HAN Yanhong,JIE Ke,ZHANG He. Systematic review of Aidi injection auxiliary GP regimen for non-small cell lung cancer[J]. Chin J Exp Tradit Med Form,2016,22(10):188-193. In Chinese with English abstract.
7. LI Youlin,PAN Jianghua,TONG Xiaochun. Effect of Addie injection combined with FOLFIRI regimen in treatment of advanced colorectal cancer[J]. Chin Arch Tradit Chin Med,2016,34(6):1473-1476. In Chinese with English abstract.
8. CUI Rongna,Guan Yu,JIN Feng.Superficial analysis of the problems associated with the instructions of Chinese traditional patent medicines containing toxic ingredients[J]. Chin J Pharmacovig,2014,11(1):42-44. In Chinese with English abstract.
9. YANG Yan,FAN Linlin,GU Lili,et al. Meta analysis of randomized controlled trials for treatment of rheumatoid arthritis by Biqi capsules[J]. J Tianjin Univ Tradit Chin Med,2014,33(6):333-338. In Chinese with English abstract.
10. GUO Jingxian,CHEN Fei,ZHUANG Wei,et al. Rational application of Annao pills,a Chinese medicine containing toxic ingredients[J]. Chin Tradit Patent Med,2014,36(8):1790-1792. In Chinese.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口